A new study reveals that only about 1 in 3 patients with prostate cancer have a successful first CT simulation, while 1 in 6 need to be rescheduled for another day.
Akeega combines niraparib, a PARP inhibitor, and abiraterone acetate, a CYP17 inhibitor, into a single tablet for BRCA2-mutated mCSPC.
Lagos, led by Professor Kingsley Ekwueme, has pioneered high-intensity focused ultrasound (HIFU) for prostate cancer treatment, positioning Nigeria as the first nation in West and Central Africa to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback